On this week’s Few & Far Between podcast episode, Biorasi’s CEO, Chris O'Brien, welcomes Karen Petrou and David Brint for an in-depth discussion on BioBonds and how they can jumpstart funding in clinical research for rare disease and other disorders.
How do today’s CEOs and founders find the balance between planning and entrepreneurship? Check out the latest episode of the Biorasi Few & Far...
With biotech, is it the destination, the journey, or both? Find out in a new episode of the Biorasi Few & Far Between podcast....
"I learned very early on that the stupidest cancer cell was cleverer than the cleverest oncologist." - Justin Stebbing, Editor-in-Chief of Oncogene, previously the...